Latest Breaking News On - Alex lobo - Page 13 : comparemela.com

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

BOSTON and ATLANTA, June 29, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of

United statesMiltonh wernerAlex loboInhibikase or companyAmerican stock transfer trust companyCompany contactSternir incExchange commissionPrnewswire inhibikase therapeutics incInhibikase therapeutics incAbelson tyrosine kinasesNasdaq capital marketAmerican stock transferTrust companyAbelson tyrosine kinaseAbleson tyrosine

Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial

LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies target.

Los angelesAlex loboIlya rachmanGabriel morrisInternational myeloma working groupImmix biopharma incCompany contactExchange commissionNexcella incImmix biopharmaPre investigational new drugChief executive officerChief financial officerMultiple myelomaUniform response criteriaTissue specific therapeutics

Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial

Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Ilya rachmanAlex loboGabriel morrisLos angelesInternational myeloma working groupNexcella incExchange commissionImmix biopharma incPre investigational new drugExecutive chairmanMultiple myelomaUniform response criteriaRisk factorImmix biopharmaAnnual report

Immix Biopharma Subsidiary Nexcella Completes Pre-IND

LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a.

Ilya rachmanGabriel morrisAlex loboLos angelesImmix biopharma incNexcella incInternational myeloma working groupExchange commissionImmix biopharmaPre investigational new drugChief executive officerChief financial officerMultiple myelomaUniform response criteriaTissue specific therapeuticsOrphan drug designation

Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial

Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Los angelesAlex loboGabriel morrisIlya rachmanExchange commissionInternational myeloma working groupImmix biopharma incNexcella incImmix biopharmaPre investigational new drugChief executive officerChief financial officerMultiple myelomaUniform response criteriaTissue specific therapeuticsOrphan drug designation